Intranasal immunotherapy and polymerized grass pollen allergens.
The effects of immunotherapy by intranasal insufflation of Lolium perenne allergens modified with glutaraldehyde (Glu-Rye) was tested by a stratified placebo-controlled trial in 16 adult subjects with hay fever. The purpose of this pilot study was to determine whether the treatment could reduce nasal sensitivity to allergen in provocation tests. Modification of the allergen was shown to include polymerization and reduced allergenicity, but retained immunogenicity. Nasal sensitivity to unmodified L. perenne allergens was measured by threshold-type quantitative nasal challenge and posterior rhinometry for measurement of nasal airway resistance. In challenge tests after a 10-week course of intranasal preseasonal treatment with Glu-Rye, nasal sensitivity was reduced, but this effect was not maintained when testing was repeated 9 months after treatment. Post-seasonal serum levels of IgE antibodies to L. perenne were also not significantly affected by the treatment.
D000281:Administration, Intranasal; D000328:Adult; D000485:Allergens / Q000008:administration & dosage*; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D007167:Immunotherapy; D008134:Long-Term Care; D046911:Macromolecular Substances; D008875:Middle Aged; D009299:Nasal Provocation Tests; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000628:therapy*
D000485:Allergens; D046911:Macromolecular Substances; D007073:Immunoglobulin E